С槼ºÖ±²¥

Object moved to here.

Red Blood Cell Transfusion: 2023 AABB International Guidelines | Critical Care Medicine | С槼ºÖ±²¥ | С槼ºÖ±²¥ Network

С槼ºÖ±²¥

[Skip to Navigation]
Sign In
1.
World Health Organization. Blood transfusion. June 8, 2022. Accessed February 23, 2023.
2.
Jones ÌýJM, Sapiano ÌýMRP, Mowla ÌýS, Bota ÌýD, Berger ÌýJJ, Basavaraju ÌýSV. ÌýHas the trend of declining blood transfusions in the United States ended? findings of the 2019 National Blood Collection and Utilization Survey.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2021;61 suppl 2 (suppl 2):S1-S10. doi:
3.
Hendrickson ÌýJE, Roubinian ÌýNH, Chowdhury ÌýD, Ìýet al; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study (REDS-III). ÌýIncidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2016;56(10):2587-2596. doi:
4.
Steele ÌýWR, Dodd ÌýRY, Notari ÌýEP, Ìýet al; Transfusion-Transmissible Infections Monitoring System (TTIMS). ÌýPrevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: the Transfusion-Transmissible Infections Monitoring System (TTIMS).Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2020;60(10):2327-2339. doi:
5.
Hibbs ÌýSP, Brunskill ÌýSJ, Donald ÌýGC, Saunders ÌýHD, Murphy ÌýMF. ÌýSetting priorities for research in blood donation and transfusion: outcome of the James Lind Alliance priority-setting partnership.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2019;59(2):574-581. doi:
6.
Mowla ÌýSJ, Sapiano ÌýMRP, Jones ÌýJM, Berger ÌýJJ, Basavaraju ÌýSV. Supplemental findings of the 2019 National Blood Collection and Utilization Survey. Transfusion. 2021;61 suppl 2 (suppl 2):S11-S35.
7.
Kacker ÌýS, Frick ÌýKD, Tobian ÌýAA. ÌýThe costs of transfusion: economic evaluations in transfusion medicine, part 1.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2013;53(7):1383-1385. doi:
8.
Stokes ÌýEA, Wordsworth ÌýS, Staves ÌýJ, Ìýet al. ÌýAccurate costs of blood transfusion: a microcosting of administering blood products in the United Kingdom National Health Service.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2018;58(4):846-853. doi:
9.
Stanworth ÌýSJ, New ÌýHV, Apelseth ÌýTO, Ìýet al. ÌýEffects of the COVID-19 pandemic on supply and use of blood for transfusion.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Haematol. 2020;7(10):e756-e764. doi:
10.
Carson ÌýJL, Grossman ÌýBJ, Kleinman ÌýS, Ìýet al Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157(1):49-58.
11.
Carson ÌýJL, Guyatt ÌýG, Heddle ÌýNM, Ìýet al. ÌýClinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage.Ìý Ìý´³´¡²Ñ´¡. 2016;316(19):2025-2035. doi:
12.
Valentine ÌýSL, Bembea ÌýMM, Muszynski ÌýJA, Ìýet al; Pediatric Critical Care Transfusion and Anemia Expertise Initiative (TAXI); Pediatric Critical Care Blood Research Network (BloodNet), and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. ÌýConsensus recommendations for RBC transfusion practice in critically ill children from the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.Ìý ÌýPediatr Crit Care Med. 2018;19(9):884-898. doi:
13.
Carson ÌýJL, Stanworth ÌýSJ, Dennis ÌýJA, Ìýet al. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô thresholds for guiding red blood cell transfusion.Ìý ÌýCochrane Database Syst Rev. 2021;12(12):CD002042.
14.
Shiffman ÌýRN. Recognizing trustworthy guidelines: the new IOM standards. Accessed January 2, 2023.
15.
Guyatt ÌýGH, Oxman ÌýAD, Vist ÌýGE, Ìýet al; GRADE Working Group. ÌýGRADE: an emerging consensus on rating quality of evidence and strength of recommendations.Ìý Ìýµþ²Ñ´³. 2008;336(7650):924-926. doi:
16.
AABB. AABB conflicts of interest disclosure form. Accessed February 23, 2023.
17.
Wang ÌýP, Wang ÌýX, Deng ÌýH, Ìýet al. ÌýRestrictive versus liberal transfusion thresholds in very low birth weight infants: a systematic review with meta-analysis.Ìý ÌýPLoS One. 2021;16(8):e0256810. doi:
18.
Maitland ÌýK, Kiguli ÌýS, Olupot-Olupot ÌýP, Ìýet al; TRACT Group. ÌýImmediate transfusion in African children with uncomplicated severe anemia.Ìý ÌýN Engl J Med. 2019;381(5):407-419. doi:
19.
Maitland ÌýK, Olupot-Olupot ÌýP, Kiguli ÌýS, Ìýet al; TRACT Group. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô volume for children with severe anemia in Africa.Ìý ÌýN Engl J Med. 2019;381(5):420-431. doi:
20.
Akyildiz ÌýB, Ulgen Tekerek ÌýN, Pamukcu ÌýO, Ìýet al. ÌýComprehensive analysis of liberal and restrictive transfusion strategies in pediatric intensive care unit.Ìý ÌýJ Trop Pediatr. 2018;64(2):118-125. doi:
21.
Morton ÌýS, Sekhar ÌýM, Smethurst ÌýH, Ìýet al. ÌýDo liberal thresholds for red cell transfusion result in improved quality of life for patients undergoing intensive chemotherapy for acute myeloid leukemia? a randomized crossover feasibility study.Ìý Ìý±á²¹±ð³¾²¹³Ù´Ç±ô´Ç²µ¾±³¦²¹. 2022;107(6):1474-1478. doi:
22.
Salehi ÌýSH, Daniali ÌýM, Motaghi ÌýP, Momeni ÌýM. ÌýThe best strategy for red blood cell transfusion in severe burn patients, restrictive or liberal: a randomized controlled trial.Ìý Ìýµþ³Ü°ù²Ô²õ. 2021;47(5):1038-1044. doi:
23.
Buckstein ÌýRJÌý, Prica A, Leber B, et al. RBC-Enhance: a randomized pilot feasibility trial of red cell transfusion thresholds in myelodysplastic syndromes.Ìý Ìýµþ±ô´Ç´Ç»å. 2020;136(suppl 1):3. doi:
24.
Higgins ÌýJP, Altman ÌýDG, Gøtzsche ÌýPC, Ìýet al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. ÌýThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.Ìý Ìýµþ²Ñ´³. 2011;343:d5928. doi:
25.
Higgins ÌýJ, Thomas ÌýJ. Cochrane Handbook for Systematic Reviews of Interventions. Accessed January 2, 2023.
26.
Schandelmaier ÌýS, Briel ÌýM, Varadhan ÌýR, Ìýet al Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192(32):E901-E906.
27.
Review Manager 5 (RevMan 5): Version 5.4. Nordic Cochrane Centre, Cochrane Collaboration; 2020.
28.
Guyatt ÌýGH, Oxman ÌýAD, Santesso ÌýN, Ìýet al. ÌýGRADE guidelines, 12: preparing summary of findings tables—binary outcomes.Ìý ÌýJ Clin Epidemiol. 2013;66(2):158-172. doi:
29.
Atkins ÌýD, Best ÌýD, Briss ÌýPA, Ìýet al; GRADE Working Group. ÌýGrading quality of evidence and strength of recommendations.Ìý Ìýµþ²Ñ´³. 2004;328(7454):1490. doi:
30.
Guyatt ÌýGH, Oxman ÌýAD, Schünemann ÌýHJ, Tugwell ÌýP, Knottnerus ÌýA. ÌýGRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.Ìý ÌýJ Clin Epidemiol. 2011;64(4):380-382. doi:
31.
Alonso-Coello ÌýP, Oxman ÌýAD, Moberg ÌýJ, Ìýet al; GRADE Working Group. ÌýGRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices, 2: clinical practice guidelines.Ìý Ìýµþ²Ñ´³. 2016;353:i2089. doi:
32.
Webert ÌýKE, Cook ÌýRJ, Couban ÌýS, Ìýet al. ÌýA multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2008;48(1):81-91.
33.
DeZern ÌýAE, Williams ÌýK, Zahurak ÌýM, Ìýet al. ÌýRed blood cell transfusion triggers in acute leukemia: a randomized pilot study.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2016;56(7):1750-1757. doi:
34.
Tay ÌýJ, Allan ÌýDS, Chatelain ÌýE, Ìýet al. ÌýLiberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial.Ìý ÌýJ Clin Oncol. 2020;38(13):1463-1473. doi:
35.
Lacroix ÌýJ, Hébert ÌýPC, Hutchison ÌýJS, Ìýet al; TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô strategies for patients in pediatric intensive care units.Ìý ÌýN Engl J Med. 2007;356(16):1609-1619. doi:
36.
Laine ÌýA, Niemi ÌýT, Schramko ÌýA. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô threshold of hemoglobin 80g/L is comparable to 100g/L in terms of bleeding in cardiac surgery: a prospective randomized study.Ìý ÌýJ Cardiothorac Vasc Anesth. 2018;32(1):131-139. doi:
37.
Gillies ÌýMA, Ghaffar ÌýS, Moppett ÌýIK, Ìýet al. ÌýA restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF).Ìý ÌýBr J Anaesth. 2021;126(1):77-86. doi:
38.
Gobatto ÌýALN, Link ÌýMA, Solla ÌýDJ, Ìýet al. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô requirements after head trauma: a randomized feasibility controlled trial.Ìý ÌýCrit Care. 2019;23(1):89-89. doi:
39.
Parker ÌýMJ. ÌýRandomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery.Ìý Ìý±õ²ÔÂá³Ü°ù²â. 2013;44(12):1916-1918. doi:
40.
Hébert ÌýPC, Wells ÌýG, Marshall ÌýJ, Ìýet al; Canadian Critical Care Trials Group. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô requirements in critical care. A pilot study.Ìý [published erratum appears in С槼ºÖ±²¥ 1995 Sep 27;274(12):944]. Ìý´³´¡²Ñ´¡. 1995;273(18):1439-1444. doi:
41.
de Almeida ÌýJP, Vincent ÌýJL, Galas ÌýFR, Ìýet al. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô requirements in surgical oncology patients: a prospective, randomized controlled trial.Ìý Ìý´¡²Ô±ð²õ³Ù³ó±ð²õ¾±´Ç±ô´Ç²µ²â. 2015;122(1):29-38. doi:
42.
Palmieri ÌýTL, Holmes ÌýJH ÌýIV, Arnoldo ÌýB, Ìýet al. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô requirement in burn care evaluation (TRIBE). A multicenter randomized prospective trial of blood transfusion in major burn injury.Ìý ÌýAnn Surg. 2017;266(4):595-602. doi:
43.
Walsh ÌýTS, Boyd ÌýJA, Watson ÌýD, Ìýet al; RELIEVE Investigators. ÌýRestrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial.Ìý ÌýCrit Care Med. 2013;41(10):2354-2363. doi:
44.
Murphy ÌýGJ, Pike ÌýK, Rogers ÌýCA, Ìýet al; TITRe2 Investigators. ÌýLiberal or restrictive transfusion after cardiac surgery.Ìý ÌýN Engl J Med. 2015;372(11):997-1008. doi:
45.
Villanueva ÌýC, Colomo ÌýA, Bosch ÌýA, Ìýet al. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô strategies for acute upper gastrointestinal bleeding.Ìý ÌýN Engl J Med. 2013;368(1):11-21. doi:
46.
Mazer ÌýCD, Whitlock ÌýRP, Fergusson ÌýDA, Ìýet al; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. ÌýRestrictive or liberal red-cell transfusion for cardiac surgery.Ìý ÌýN Engl J Med. 2017;377(22):2133-2144. doi:
47.
Hébert ÌýPC, Wells ÌýG, Blajchman ÌýMA, Ìýet al. ÌýA multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.Ìý ÌýN Engl J Med. 1999;340(6):409-417. doi:
48.
Bergamin ÌýFS, Almeida ÌýJP, Landoni ÌýG, Ìýet al. ÌýLiberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients: randomized controlled trial.Ìý ÌýCrit Care Med. 2017;45(5):766-773. doi:
49.
Holst ÌýLB, Haase ÌýN, Wetterslev ÌýJ, Ìýet al; TRISS Trial Group; Scandinavian Critical Care Trials Group. ÌýLower versus higher hemoglobin threshold for transfusion in septic shock.Ìý ÌýN Engl J Med. 2014;371(15):1381-1391. doi:
50.
Lotke ÌýPA, Barth ÌýP, Garino ÌýJP, Cook ÌýEF. ÌýPredonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration.Ìý ÌýJ Arthroplasty. 1999;14(6):647-650. doi:
51.
Grover ÌýM, Talwalkar ÌýS, Casbard ÌýA, Ìýet al. ÌýSilent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty.Ìý ÌýVox Sang. 2006;90(2):105-112. doi:
52.
Blair ÌýSD, Janvrin ÌýSB, McCollum ÌýCN, Greenhalgh ÌýRM. ÌýEffect of early blood transfusion on gastrointestinal haemorrhage.Ìý ÌýBr J Surg. 1986;73(10):783-785. doi:
53.
Foss ÌýNB, Kristensen ÌýMT, Jensen ÌýPS, Palm ÌýH, Krasheninnikoff ÌýM, Kehlet ÌýH. ÌýThe effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2009;49(2):227-234. doi:
54.
Carson ÌýJL, Terrin ÌýML, Barton ÌýFB, Ìýet al. ÌýA pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 1998;38(6):522-529. doi:
55.
Møller ÌýA, Nielsen ÌýHB, Wetterslev ÌýJ, Ìýet al. ÌýLow vs high hemoglobin trigger for transfusion in vascular surgery: a randomized clinical feasibility trial.Ìý Ìýµþ±ô´Ç´Ç»å. 2019;133(25):2639-2650. doi:
56.
Webert ÌýKE, Cook ÌýRJ, Couban ÌýS, Ìýet al. ÌýA multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2008;48(1):81-91.
57.
Cooper ÌýHA, Rao ÌýSV, Greenberg ÌýMD, Ìýet al. ÌýConservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study).Ìý ÌýAm J Cardiol. 2011;108(8):1108-1111. doi:
58.
Carson ÌýJL, Brooks ÌýMM, Abbott ÌýJD, Ìýet al. ÌýLiberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease.Ìý ÌýAm Heart J. 2013;165(6):964-971.e1. doi:
59.
Bush ÌýRL, Pevec ÌýWC, Holcroft ÌýJW. ÌýA prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients.Ìý ÌýAm J Surg. 1997;174(2):143-148. doi:
60.
Hajjar ÌýLA, Vincent ÌýJL, Galas ÌýFR, Ìýet al. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô requirements after cardiac surgery: the TRACS randomized controlled trial.Ìý Ìý´³´¡²Ñ´¡. 2010;304(14):1559-1567. doi:
61.
Gregersen ÌýM, Borris ÌýLC, Damsgaard ÌýEM. ÌýPostoperative blood transfusion strategy in frail, anemic elderly patients with hip fracture: the TRIFE randomized controlled trial.Ìý ÌýActa Orthop. 2015;86(3):363-372. doi:
62.
Jairath ÌýV, Kahan ÌýBC, Gray ÌýA, Ìýet al. ÌýRestrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 2015;386(9989):137-144. doi:
63.
Ducrocq ÌýG, Gonzalez-Juanatey ÌýJR, Puymirat ÌýE, Ìýet al; REALITY Investigators. ÌýEffect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial.Ìý Ìý´³´¡²Ñ´¡. 2021;325(6):552-560. doi:
64.
Carson ÌýJL, Terrin ÌýML, Noveck ÌýH, Ìýet al; FOCUS Investigators. ÌýLiberal or restrictive transfusion in high-risk patients after hip surgery.Ìý ÌýN Engl J Med. 2011;365(26):2453-2462. doi:
65.
Carson ÌýJL. ÌýMyocardial Ischemia and Transfusion (MINT). NationalÌý Ìý³¢¾±²ú°ù²¹°ù²â of Medicine. Accessed January 7, 2023.
66.
Robitaille ÌýN, Lacroix ÌýJ, Alexandrov ÌýL, Ìýet al. ÌýExcess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a Canadian Blood and Marrow Transplant Group trial.Ìý ÌýBiol Blood Marrow Transplant. 2013;19(3):468-473. doi:
67.
Cholette ÌýJM, Powers ÌýKS, Alfieris ÌýGM, Ìýet al. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô of cell saver salvaged blood in neonates and infants undergoing open heart surgery significantly reduces RBC and coagulant product transfusions and donor exposures: results of a prospective, randomized, clinical trial.Ìý ÌýPediatr Crit Care Med. 2013;14(2):137-147. doi:
68.
Cholette ÌýJM, Swartz ÌýMF, Rubenstein ÌýJ, Ìýet al. ÌýOutcomes using a conservative versus liberal red blood cell transfusion strategy in infants requiring cardiac operation.Ìý ÌýAnn Thorac Surg. 2017;103(1):206-214. doi:
69.
de Gast-Bakker ÌýDH, de Wilde ÌýRB, Hazekamp ÌýMG, Ìýet al. ÌýSafety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized controlled trial.Ìý ÌýIntensive Care Med. 2013;39(11):2011-2019. doi:
70.
Vuille-Lessard ÌýE, Boudreault ÌýD, Girard ÌýF, Ruel ÌýM, Chagnon ÌýM, Hardy ÌýJF. ÌýRed blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study.Ìý Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô. 2010;50(10):2117-2124. doi:
71.
Heddle ÌýNM, Cook ÌýRJ, Arnold ÌýDM, Ìýet al. ÌýEffect of short-term vs long-term blood storage on mortality after transfusion.Ìý ÌýN Engl J Med. 2016;375(20):1937-1945. doi:
72.
Cooper ÌýDJ, McQuilten ÌýZK, Nichol ÌýA, Ìýet al; TRANSFUSE Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. ÌýAge of red cells for transfusion and outcomes in critically ill adults.Ìý ÌýN Engl J Med. 2017;377(19):1858-1867. doi:
73.
Hamm ÌýCW, Bassand ÌýJP, Agewall ÌýS, Ìýet al; ESC Committee for Practice Guidelines. ÌýESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).Ìý ÌýEur Heart J. 2011;32(23):2999-3054. doi:
74.
Ferraris ÌýVA, Brown ÌýJR, Despotis ÌýGJ, Ìýet al; Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion; International Consortium for Evidence Based Perfusion. Ìý2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines.Ìý ÌýAnn Thorac Surg. 2011;91(3):944-982. doi:
75.
Retter ÌýA, Wyncoll ÌýD, Pearse ÌýR, Ìýet al; British Committee for Standards in Haematology. ÌýGuidelines on the management of anaemia and red cell transfusion in adult critically ill patients.Ìý ÌýBr J Haematol. 2013;160(4):445-464. doi:
76.
Rogers GM, Cela D, Cleeland C, et al. NCCN Guidelines Version 2.2014, Cancer- and Chemotherapy-Induced Anemia: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). National Comprehensive Cancer Network; 2013.
77.
American Society of Anesthesiologists Task Force on Perioperative Blood Management. ÌýPractice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management.Ìý Ìý´¡²Ô±ð²õ³Ù³ó±ð²õ¾±´Ç±ô´Ç²µ²â. 2015;122(2):241-275. doi:
78.
Qaseem ÌýA, Humphrey ÌýLL, Fitterman ÌýN, Starkey ÌýM, Shekelle ÌýP; Clinical Guidelines Committee of the American College of Physicians. ÌýTreatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.Ìý ÌýAnn Intern Med. 2013;159(11):770-779. doi:
79.
Alexander ÌýJ, Cifu ÌýAS. Ìý°Õ°ù²¹²Ô²õ´Ú³Ü²õ¾±´Ç²Ô of red blood cells.Ìý Ìý´³´¡²Ñ´¡. 2016;316(19):2038-2039. doi:
80.
Kozek-Langenecker ÌýSA, Ahmed ÌýAB, Afshari ÌýA, Ìýet al. ÌýManagement of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016.Ìý ÌýEur J Anaesthesiol. 2017;34(6):332-395. doi:
81.
Mueller ÌýMM, Van Remoortel ÌýH, Meybohm ÌýP, Ìýet al; ICC PBM Frankfurt 2018 Group. ÌýPatient blood management: recommendations from the 2018 Frankfurt Consensus Conference.Ìý Ìý´³´¡²Ñ´¡. 2019;321(10):983-997. doi:
82.
Raphael ÌýJ, Mazer ÌýCD, Subramani ÌýS, Ìýet al. ÌýSociety of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients.Ìý ÌýJ Cardiothorac Vasc Anesth. 2019;33(11):2887-2899. doi:
83.
Tibi ÌýP, McClure ÌýRS, Huang ÌýJ, Ìýet al. ÌýSTS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management.Ìý ÌýAnn Thorac Surg. 2021;112(3):981-1004. doi:
Views 82,599
Special Communication
October 12, 2023

Red Blood Cell Transfusion: 2023 AABB International Guidelines

Author Affiliations
  • 1Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
  • 2Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom
  • 3NHSBT, Oxford, United Kingdom
  • 4Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
  • 5Department of Transfusion Medicine, NHS Blood and Transplant, Oxford, United Kingdom
  • 6Departments of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, Ontario, Canada
  • 7Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester
  • 8Cochrane Injuries Group, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • 9Department of Laboratory Medicine, University of California, San Francisco
  • 10Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis
  • 11Patient partner
  • 12Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri
  • 13Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
  • 14Departments of Anesthesiology and Pathology and Laboratory Medicine, University of Wisconsin–Madison, Madison
  • 15Department of Pathology, New York University Grossman School of Medicine, New York
  • 16NYC Health + Hospitals/Bellevue, New York, New York
  • 17Department of Surgery, Division of Trauma, Surgical Critical Care and Surgical Emergencies, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 18Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
  • 19Department of Pathology, University of Utah, Salt Lake City
  • 20Pathology Associates of Albuquerque, Albuquerque, New Mexico
  • 21Department of Laboratory Medicine and Pathobiology, University of Toronto and St Michael’s Hospital–Unity Health Toronto, Toronto, Ontario, Canada
  • 22Department of Medicine, University of Chicago, Chicago, Illinois
  • 23Department of Pathology, University of New Mexico, Albuquerque
  • 24Department of Pathology and Laboratory Medicine, UT Health San Antonio, San Antonio, Texas
  • 25Department of Laboratory Medicine and Pathology, Seattle Children’s Hospital, Seattle, Washington
  • 26Department of Pathology, Johns Hopkins University, Baltimore, Maryland
  • 27Department of Unit Transfusion Medicine (UTG), Sanquin Blood Bank, Amsterdam, the Netherlands
  • 28Department Hematology, Erasmus Medical Center, Rotterdam, the Netherlands
  • 29Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 30Department of Haematology, Monash Health, Monash University School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia
  • 31Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis
  • 32Department of Laboratory Medicine and Pathology, University of Washington, Seattle
С槼ºÖ±²¥. 2023;330(19):1892-1902. doi:10.1001/jama.2023.12914
Abstract

ImportanceÌý Red blood cell transfusion is a common medical intervention with benefits and harms.

ObjectiveÌý To provide recommendations for use of red blood cell transfusion in adults and children.

Evidence ReviewÌý Standards for trustworthy guidelines were followed, including using Grading of Recommendations Assessment, Development and Evaluation methods, managing conflicts of interest, and making values and preferences explicit. Evidence from systematic reviews of randomized controlled trials was reviewed.

FindingsÌý For adults, 45 randomized controlled trials with 20 599 participants compared restrictive hemoglobin-based transfusion thresholds, typically 7 to 8 g/dL, with liberal transfusion thresholds of 9 to 10 g/dL. For pediatric patients, 7 randomized controlled trials with 2730 participants compared a variety of restrictive and liberal transfusion thresholds. For most patient populations, results provided moderate quality evidence that restrictive transfusion thresholds did not adversely affect patient-important outcomes. Recommendation 1: for hospitalized adult patients who are hemodynamically stable, the international panel recommends a restrictive transfusion strategy considering transfusion when the hemoglobin concentration is less than 7 g/dL (strong recommendation, moderate certainty evidence). In accordance with the restrictive strategy threshold used in most trials, clinicians may choose a threshold of 7.5 g/dL for patients undergoing cardiac surgery and 8 g/dL for those undergoing orthopedic surgery or those with preexisting cardiovascular disease. Recommendation 2: for hospitalized adult patients with hematologic and oncologic disorders, the panel suggests a restrictive transfusion strategy considering transfusion when the hemoglobin concentration is less than 7 g/dL (conditional recommendations, low certainty evidence). Recommendation 3: for critically ill children and those at risk of critical illness who are hemodynamically stable and without a hemoglobinopathy, cyanotic cardiac condition, or severe hypoxemia, the international panel recommends a restrictive transfusion strategy considering transfusion when the hemoglobin concentration is less than 7 g/dL (strong recommendation, moderate certainty evidence). Recommendation 4: for hemodynamically stable children with congenital heart disease, the international panel suggests a transfusion threshold that is based on the cardiac abnormality and stage of surgical repair: 7 g/dL (biventricular repair), 9 g/dL (single-ventricle palliation), or 7 to 9 g/dL (uncorrected congenital heart disease) (conditional recommendation, low certainty evidence).

Conclusions and RelevanceÌý It is good practice to consider overall clinical context and alternative therapies to transfusion when making transfusion decisions about an individual patient.

×